Connect with us

Featured

Harbor Diversified Inc (OTCMKTS: HRBR) Air Wisconsin Airlines a Microcapdaily Top Runner (More on United Capacity Purchase Agreement 02/2023 & CBA Amendable Dates for HRBR Union Employees Starting 09/2022)

Published

on

Harbor Diversified Inc (OTCMKTS: HRBR) continues to trade over $2 support levels in recent trading remaining fairly liquid trading between $50,000 and $500,000 per day in dollar volume. HRBR was a 2020 reverse merger that Microcapdaily first reported on HRNR on November 10, 2020 when HRBR was $0.08 per share. Over the past 3 years Harbor Diversified has grown from operating at a loss of $19 million in 2019 to $91.8 million in net income in 2021 with similar numbers expected in 2022. Part of the reason HRBR does not get more traction is because the Company does not issue press releases and while they are “pink current” the Company is an SEC filer recently filings its 10Q on May 9. The Company is making all the right moves, they are profitable and currently hiring for many positions and they instituted a stock buyback program which is ongoing. During 2021 the Company acquired 1,547,006 shares of its common stock on the open market.  

HRBR derives all of its revenues from an agreement with United airlines first signed in February 2017, which was amended in October 2020 and April 2021. The United capacity purchase agreement expires in February 2023, subject to a wind-down period. Negotiations are ongoing with United as well as with another major carrier. United has announced their fleet strategy includes reducing their 50-seat aircraft departures from 33% of total departures to 10% by 2026. Also looming is the CBA amendable dates for many of Harbor’s union employees. 82% of Harbor’s employees are represented by a union. Negotiations are currently ongoing with their dispatcher union members, and CBA amenable dates begin 09/2022 with their office, fleet and passenger service employees, and continue 10/2022 with their flight attendants, and 11/2022 with their pilots. These employees likely understand the scope of their negotiating leverage. Due to, inter alia, a rising interest rate environment, pilot, maintenance, and flight attendance employment shortages, and recovering North American travel United could extend or enter into a new contract with Harbor given completed CBA’s. Harbor’s employees and operational experience are difficult to replace and would drive the outcome. A possibility exists of Harbor selling their current fleet, and leasing different jets or operating United jets. Harbor hired their CFO from United to increase their odds. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Harbor Diversified Inc (OTCMKTS: HRBR) is a non-operating holding company that is the parent of a consolidated group of subsidiaries, including AWAC Aviation, Inc. which is the sole member of Air Wisconsin Airlines LLC a regional air carrier. Harbor is also the direct parent of three other subsidiaries: (1) Lotus Aviation Leasing, LLC, which leases flight equipment to Air Wisconsin, (2) Air Wisconsin Funding LLC, which provides flight equipment financing to Air Wisconsin, and (3) Harbor Therapeutics, Inc., which is a non-operating entity with no material assets.

Microcapdaily was among the first to report on HRBR back on November 10, 2020 when HRBR was $0.08 per share before the stock skyrocketed to highs of $3.08 in summer 2021 up over 3800% from our initial article. In our article titled “Air Wisconsin Airlines; the Rise of Harbor Diversified Inc (OTCMKTS: HRBR) by Boe Rimes, November 10, 2020 we reported: “Harbor Diversified Inc (OTCMKTS: HRBR) is making an explosive move up the charts on a massive surge of volume quickly emerging as among the most exciting stories in small caps. HRBR is quickly getting noticed by top traders and the stock has exploded northbound off its $0.05 base.” 

Air Wisconsin operates a fleet of 64 CRJ-200 regional jets under a capacity purchase agreement. with its sole major airline partner, United Airlines, Inc., with a presence at both Chicago O’Hare and Washington-Dulles, two of United’s key domestic hubs. All of Air Wisconsin’s flights are operated as United Express pursuant to the terms of the United capacity purchase agreement. More than 99% of the Company’s operating revenues for the years ended December 31, 2021 and 2020 was derived from operations associated with the United capacity purchase agreement. 

United and Air Wisconsin entered into the United capacity purchase agreement in February 2017, which was amended in October 2020 and April 2021. The United capacity purchase agreement expires in February 2023, subject to a wind-down period. 

The fleet of CRJ-200 jets, were all manufactured by Bombardier, Inc. and offer many of the capabilities and amenities of larger commercial jet aircraft, including flight attendant service, a stand-up cabin, limited overhead and under seat storage, a lavatory and a galley that allows for in-flight snack and beverage service. The CRJ-200 regional jet has a speed comparable to larger aircraft operated by major airlines and has a range of approximately 1,585 miles. 

To Find out the inside Scoop on HRBR Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HRBR

HRBR has an impressive balance sheet for a stock that is “pink current” according to OTCMarkets. Harbor Diversified is an SEC filer and filed its 10k on March 31, and its 10Q on May 9 for the 3 months ended March 31, 2022 at which time the Company had $384.9 million in assets including $119 million in marketable securities and $25 million in the treasury vs. $165 million in liabilities. Revenues were $66,968,000 for the 3 months ended March 31, 2022 up over the $49,756,000 in revenues the Company posted for the same period the previous year when COVID shutdown affected flights more than they have this year. Net income for the 3 months period was $9 million. 

Alluvial Fund, LP, founded in 2014 and run by David Waters, CFA holds a position in HRBR and recenlty wrote of Harbor Diversified in their Q1 letter to partners. The letter states: “We have added a new special situation to our collection: Harbor Diversified. Harbor is a holding company for Wisconsin Airlines. Ordinarily I have little interest in airlines of any kind, but Harbor Diversified is a special case. At around $2.40 per share, Harbor trades at a steep discount to liquidation value. Harbor trades so cheaply because Air Wisconsin’s capacity agreement with United Airlines expires in February 2023 and United has declined to renew the contract on the same terms. Air Wisconsin is in discussions with United and other airlines on a new contract, but there is a material chance that a contract will not be secured and Air Wisconsin’s fleet will be grounded come next February. ut even in the case that Air Wisconsin fails to achieve a new contract, Harbor’s existing working capital, fleet, and remaining earnings are worth well in excess of the company’s trading price. At year-end, the company had over $2 per share in cash, securities, and interest-bearing receivables net of debt, all future lease payments, and preferred stock liquidation preference. Air Wisconsin will produce pre-tax cash flow of nearly $90 million over the length of its remaining contract. And then there is the fleet itself. Air Wisconsin owns 64 Bombardier CRJ200s. These aircraft are old and the CRJ200 itself is not exactly a popular jet, but they are worth something. At even $250,000 each, less than 15% of book value, that’s $16 million or 25 cents per share. We expect that over the course of the year, Harbor Diversified will either announce a new contract for Air Wisconsin or will begin preparations for an orderly liquidation. In a liquidation scenario, shares are worth north of $3. If a new contract is secured, their value could be substantially higher as investors begin valuing the company as a going concern instead of a liquidation story. For its part, Air Wisconsin seems to be optimistic about securing a new contract. The company is very active on the hiring front, seeking pilots, flight attendants, and mechanics; not exactly the behavior of an airline that expects to shutter permanently in 10 months. 

The controlling shareholders of HRBR are Amun LLC with 20 million shares and representing 31.4% of the Company and Southshore Aircraft Holdings, LLC with 16.5 million shares representing 25.9% of the Company. Richard A. Bartlett, a direction of the Company is a member of the board of managers of Amun, and owns 25.6% of the outstanding equity interests of Amun. Mr. Bartlett also owns 25.6% of the outstanding equity interests of Southshore Aircraft Holdings, LLC making him an indirect owner of 57.3% of HRBR. Mr. Bartlett does not control voting or investment decisions made by Amun or by Southshore and disclaims beneficial ownership of the shares held by Southshore and by Amun, except to the extent of his pecuniary interest therein. 

For more on HRBR Subscribe to MicroCapDaily Right Now!

Currently trading at a $104 million market valuation HRBR has 47,053,806 shares outstanding. HRBR has $384 million in assets including $25 million in the treasury and $136 million in marketable securities vs. 165 million in liabilities. Over the past 3 years Harbor Diversified has grown from operating at a loss of $19 million in 2019 to $91.8 million in net income in 2021 with similar numbers expected in 2022. The Company also has a stock buyback program in place and acquired 1,547,006 shares of its common stock on the open market during 2021 with the same expected this year. There is a lot of uncertainty surrounding HRBR and its agreement with United airlines which accounts for all of the Company’s revenues, first signed in February 2017, and amended in October 2020 and April 2021. The United capacity purchase agreement expires in February 2023, subject to a wind-down period. United has not renewed the Negotiations are ongoing with United as well as with another major carrier. United has not renewed the purchase agreement and if they don’t HRBR may be forced to liquidate its assets. Also looming is the CBA amendable dates for many of Harbor’s union employees. 82% of Harbor’s employees are represented by a union. Negotiations are currently ongoing with their dispatcher union members, and CBA amenable dates begin 09/2022 with their office, fleet and passenger service employees, and continue 10/2022 with their flight attendants, and 11/2022 with their pilots. These employees likely understand the scope of their negotiating leverage. Due to, inter alia, a rising interest rate environment, pilot, maintenance, and flight attendance employment shortages, and recovering North American travel United could extend or enter into a new contract with Harbor given completed CBA’s. Harbor’s employees and operational experience are difficult to replace and would drive the outcome. A possibility exists of Harbor selling their current fleet, and leasing different jets or operating United jets. Harbor hired their CFO from United to increase their odds. If HRBR announces a new contract between Air Wisconsin and United the stock will soar, if HRBR is unable to renew the contract Aire Wiscon may have to begin preparations for an orderly liquidation. In a liquidation scenario, shares are worth north of $3. No matter what happens Microcapdaily will be there reporting on it as it happens. We will be updating on HRBR when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HRBR either long or short and we have not been compensated for this article.

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

on

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Featured

Femasys’ (NASDAQ: FEMY) FemaSeed Receives FDA Nod: A Game-Changer for Infertility Treatment

Published

on

Femasys Inc. (NASDAQ: FEMY) hit a massive milestone and saw shares soar by a whopping 346%. The reason? The United States Food and Drug Administration (FDA) has given the thumbs up for the commercialization of FemaSeed, a game-changing option for artificial insemination aiming to boost the natural fertilization process.

FemaSeed:

It’s a breakthrough treatment for infertility, designed to carry sperm right to where conception happens in a woman’s fallopian tube. This breakthrough could change the game in infertility treatments by offering a less invasive option compared to heavy hitters like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), potentially reducing the risk of complications during the procedure.

Kathy Lee-Sepsick, Femasys’ founder and CEO, is beyond excited about the FDA’s green light for FemaSeed. She highlights how this could be a game-changer in providing infertility treatments that are less of a burden. The FDA clearance is a testament to successful teamwork with the FDA and a major step forward in making this new technology available to those struggling with infertility.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The rising numbers of infertility cases in the United States (about 10 million women, as per the Center for Disease Control) show how crucial it is to have accessible and effective infertility treatments. FemaSeed is ready to meet this need by offering an affordable and efficient option for those dealing with infertility.

Here’s an interesting tidbit: FemaSeed works in harmony with FemVue, Femasys’ FDA-cleared diagnostic device. FemVue lets doctors perform an in-office ultrasound assessment of the fallopian tubes, helping diagnose infertility even before going for FemaSeed.

But wait, there’s more! Femasys isn’t just about FemaSeed. They’re also charging ahead with FemBloc, their lead candidate for permanent birth control in late-stage clinical development. Their commitment is to provide accessible solutions for women’s health, covering unmet needs with a range of innovative in-office products.

In a nutshell, Femasys is all about empowering women and couples facing fertility challenges. Their aim? To provide cost-effective and less invasive infertility treatments, backed by innovative diagnostic solutions. With this FDA clearance for FemaSeed, Femasys is a step closer to achieving this mission and leaving a lasting impact in the realm of women’s healthcare.

We will update you on FEMY when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by DigitalMarketingAgency from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.